Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ENULOSE vs CLENPIQ
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Lactulose is a synthetic disaccharide that is not absorbed from the gastrointestinal tract. It is metabolized by colonic bacteria to form low molecular weight organic acids, which lower the colonic p H and increase osmotic pressure, resulting in increased stool volume and laxative effect. In hepatic encephalopathy, the acidification of the colon inhibits the growth of ammonia-producing bacteria and promotes the conversion of ammonia to ammonium ion, which is trapped in the colon and excreted, thereby reducing systemic ammonia levels.
Picosulfate is hydrolyzed by colonic bacteria to the active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), which stimulates colonic peristalsis and promotes fluid and electrolyte accumulation in the colon. Magnesium oxide and citric acid generate magnesium citrate, an osmotic agent that draws water into the colon. Combined effects induce bowel cleansing.
Treatment of constipation,Portal-systemic encephalopathy (including the prevention and treatment of hepatic coma)
Cleansing of the colon as a preparation for colonoscopy in adults
15-45 m L orally once daily, titrated to produce 2-3 soft stools per day. Maximum 60 m L per day.
Two separate doses: first dose (5 mg prucalopride + 10 mg bisacodyl) orally, followed by a second dose (5 mg prucalopride + 10 mg bisacodyl) orally 6-12 hours later. Total dose: 10 mg prucalopride + 20 mg bisacodyl.
Terminal elimination half-life is 2.1 hours in normal renal function; prolonged to up to 6 hours in renal impairment.
Sodium picosulfate: terminal half-life 7.4 hours (clinically not relevant as action is colonic); magnesium oxide and citric acid produce bicarbonate; half-life not applicable for osmotic component
Lactulose is not metabolized in the human small intestine due to the absence of appropriate enzymes. It reaches the colon unchanged and is fermented by colonic bacteria (e.g., Lactobacillus, Bacteroides) into short-chain fatty acids (lactic acid, acetic acid, and formic acid) and gases (hydrogen, carbon dioxide).
Bisacodyl (picosulfate) is hydrolyzed by colonic bacteria to its active metabolite BHPM; magnesium citrate acts locally.
Primarily renal (95% unchanged by glomerular filtration); biliary/fecal less than 5%.
Primarily fecal (97–98%) as unchanged drug; negligible renal excretion (<2%)
Negligible (<1%), not bound to plasma proteins.
Sodium picosulfate: <5% bound to plasma proteins
Vd approximately 0.25 L/kg, primarily confined to extracellular fluid.
Sodium picosulfate: Vd ~0.2 L/kg (confined mainly to extracellular fluid, low tissue penetration)
Oral: very low (<3%) as minimally absorbed; rectal: negligible systemic absorption.
Oral (sodium picosulfate): low systemic bioavailability (<10%) due to extensive first-pass activation in colon; magnesium citrate is a locally active osmotic agent with negligible systemic absorption
No dose adjustment required for renal impairment; use with caution in severe renal impairment due to electrolyte disturbances.
Contraindicated if e GFR < 30 m L/min/1.73 m². For e GFR 30-59 m L/min/m²: reduce total prucalopride dose to 5 mg (i.e., single administration only).
No specific adjustment recommended; monitor for electrolyte imbalances in severe hepatic impairment.
Contraindicated in severe hepatic impairment (Child-Pugh class C). No dose adjustment required for mild to moderate impairment (Child-Pugh A or B).
Infants and children: 2.5-10 m L orally once daily, adjusted to produce 2-3 soft stools per day. Maximum 40 m L per day.
Not approved for use in pediatric patients (<18 years). Safety and efficacy not established.
Start at lower end of dosing range (15-30 m L daily) due to increased risk of electrolyte disturbances and dehydration. Monitor serum electrolytes.
No specific dose adjustment required solely based on age. Consider renal function (e GFR) and overall frailty; use conservative dosing in elderly with renal impairment (see renal_adjustment).
None.
WARNING: RISK OF SERIOUS FLUID AND ELECTROLYTE ABNORMALITIES. CLENPIQ can cause significant fluid and electrolyte shifts, which may lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment. Monitor and correct electrolytes before use in patients at risk.
Diabetic patients should use with caution due to the sugar content. Prolonged use may lead to electrolyte disturbances (e.g., hypernatremia, hypokalemia). Use with caution in patients with galactosemia or lactose intolerance, as lactulose may contain trace amounts of lactose. Excessive dosing may cause diarrhea and fluid loss.
Risk of fluid and electrolyte abnormalities,Cardiac arrhythmias due to electrolyte imbalance,Seizures associated with electrolyte abnormalities,Renal impairment,Mucosal ulceration,Use with caution in patients with impaired gag reflex, reflux, or aspiration risk,Colonic mucosal aphthous ulcerations
Patients with galactosemia (since lactulose contains galactose and may increase galactose levels), intestinal obstruction, or a history of hypersensitivity to lactulose or any component of the formulation.
Gastrointestinal obstruction,Gastric retention,Bowel perforation,Toxic colitis,Toxic megacolon,Ileus,Hypersensitivity to any component,Severe renal impairment (e GFR <30 m L/min/1.73m²)
No significant food interactions. May be mixed with fruit juice, water, or milk to mask sweet taste. Lactose-containing products may cause additional gas and bloating in lactose-intolerant patients.
Avoid solid food during bowel preparation. Only clear liquids (water, clear broth, black coffee/tea, clear fruit juices without pulp, gelatin, popsicles) are permitted. Do not consume milk, cream, or any dairy products. Avoid red or purple colored liquids that may be mistaken for blood during colonoscopy. Do not consume alcohol.
Pregnancy Category B. No evidence of teratogenicity in animal studies; inadequate human data in first trimester. Second and third trimester: No known fetal risks associated with therapeutic doses.
No adequate and well-controlled studies in pregnant women. In animal reproduction studies, oral administration of picosulfate sodium plus magnesium oxide (components of CLENPIQ) to pregnant rats during organogenesis at doses up to 1.2 times the human dose (based on body surface area) did not produce fetal harm. However, because animal studies are not always predictive of human response, CLENPIQ should be used during pregnancy only if clearly needed. During the first trimester, consider alternative bowel preparation to avoid any theoretical risk. In second and third trimesters, use only if potential benefit justifies potential risk to fetus.
Excreted in breast milk in small amounts; M/P ratio not established. Considered compatible with breastfeeding, but monitor infant for gastrointestinal effects.
Excretion in human milk unknown. M/P ratio not available. Because many drugs are excreted in human milk, caution should be exercised when CLENPIQ is administered to a nursing woman. Consider temporary discontinuation of breastfeeding during the 24-hour period after CLENPIQ administration.
No pharmacokinetic changes requiring dose adjustment during pregnancy. Standard dosing applies.
No dose adjustment recommendations available due to lack of pharmacokinetic studies in pregnancy. However, physiological changes in pregnancy (increased plasma volume, renal blood flow) may affect drug disposition; use lowest effective dose and ensure adequate hydration. No specific dose reduction recommended.
ENULOSE (lactulose) is a non-absorbable disaccharide used for constipation and hepatic encephalopathy. Monitor for electrolyte disturbances, especially hypernatremia, with prolonged use. In hepatic encephalopathy, titrate to 2-3 soft stools per day. Onset of action for constipation is 24-48 hours. Avoid in patients with galactosemia.
CLENPIQ (sodium picosulfate, magnesium oxide, and citric acid) is a colonoscopy preparation. Ensure adequate hydration before, during, and after use. Common adverse effects include nausea, vomiting, and abdominal distension. Contraindicated in patients with severe renal impairment (Cr Cl <30 m L/min), gastrointestinal obstruction, ileus, or known hypersensitivity. Avoid use within 1 hour of antacids or medications that affect gastrointestinal motility.
Take with or without food. Mix with juice, water, or milk to improve taste.,For constipation: effect may take 24-48 hours. Do not exceed prescribed dose.,For hepatic encephalopathy: maintain 2-3 soft stools daily; adjust dose as directed.,Common side effects include bloating, gas, and cramping. These usually improve with continued use.,Contact your doctor if you experience severe diarrhea, vomiting, or signs of dehydration.,Store at room temperature, away from heat and moisture.
Take CLENPIQ as a split-dose regimen: one bottle the evening before and one bottle the morning of the colonoscopy.,Do not take any other laxatives or bowel preparations concurrently.,Stay hydrated by drinking clear liquids before and after each dose.,Do not eat solid food during the preparation period; only clear liquids are allowed.,Common side effects include nausea, bloating, and abdominal cramps; contact your doctor if severe or persistent.,Avoid driving or operating machinery if you feel dizzy or lightheaded.,Inform your doctor of all medications, especially diuretics, ACE inhibitors, ARBs, NSAIDs, or any drugs affecting kidney function.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ENULOSE vs CLENPIQ, answered by our medical review team.
ENULOSE is a Laxative that works by Lactulose is a synthetic disaccharide that is not absorbed from the gastrointestinal tract. It is metabolized by colonic bacteria to form low molecular weight organic acids, which lower the colonic p H and increase osmotic pressure, resulting in increased stool volume and laxative effect. In hepatic encephalopathy, the acidification of the colon inhibits the growth of ammonia-producing bacteria and promotes the conversion of ammonia to ammonium ion, which is trapped in the colon and excreted, thereby reducing systemic ammonia levels.. CLENPIQ is a Laxative that works by Picosulfate is hydrolyzed by colonic bacteria to the active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), which stimulates colonic peristalsis and promotes fluid and electrolyte accumulation in the colon. Magnesium oxide and citric acid generate magnesium citrate, an osmotic agent that draws water into the colon. Combined effects induce bowel cleansing.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ENULOSE and CLENPIQ depend on the specific clinical indication. These are both Laxative agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ENULOSE is: 15-45 m L orally once daily, titrated to produce 2-3 soft stools per day. Maximum 60 m L per day.. The standard adult dose of CLENPIQ is: Two separate doses: first dose (5 mg prucalopride + 10 mg bisacodyl) orally, followed by a second dose (5 mg prucalopride + 10 mg bisacodyl) orally 6-12 hours later. Total dose: 10 mg prucalopride + 20 mg bisacodyl.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ENULOSE and CLENPIQ in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ENULOSE is classified as Category C. Pregnancy Category B. No evidence of teratogenicity in animal studies; inadequate human data in first trimester. Second and third trimester: No known fetal risks associated with th. CLENPIQ is classified as Category C. No adequate and well-controlled studies in pregnant women. In animal reproduction studies, oral administration of picosulfate sodium plus magnesium oxide (components of CLENPIQ) to. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.